Back to research

Research paper

Stiripentol in developmental and epileptic encephalopathies

Review of stiripentol use in DEEs beyond its primary Dravet indication. Covers off-label DEE-SWAS experience, response rates, and tolerability.

Indexed context

Wheless JW, et al.

stiripentoldeesasmdravetreview2026

Markdown path

content/research/papers/2026-wheless-stiripentol-dees.md

Findings

Review of stiripentol use in DEEs beyond its primary Dravet indication. Covers off-label DEE-SWAS experience, response rates, and tolerability.

Why it may matter for Levi

Stiripentol is not on Levi's current ASM list. In refractory DEE-SWAS it is a potential add-on, particularly if clobazam is co-administered (stiripentol increases clobazam levels). Worth flagging as a downstream option if initial escalation paths underperform.

Paper text

Wheless et al. (2026) — Stiripentol in DEEs

Source

  • Pediatric Neurology, 2026.

Why in corpus

Review/report on stiripentol use in developmental and epileptic encephalopathies, with emerging applicability to DEE-SWAS.

Key findings

  • Stiripentol (GABAergic enhancer, positive allosteric modulator at GABA-A) reviewed across developmental epileptic encephalopathies.
  • Emerging use as adjunctive therapy in DEE-SWAS.
  • Strongest established evidence is in Dravet syndrome.

Levi-relevant takeaways

  • Stiripentol is not currently on Levi's treatment path. Worth keeping as a contingent option if multiple standard tiers fail.
  • US availability is mostly via the Dravet indication; off-label use in DEE-SWAS would require specialist involvement.
  • Mechanistically complements high-dose benzodiazepines (both work via GABA-A), so not additive to clobazam if that's the parallel option being considered.